{
    "nct_id": "NCT05662397",
    "official_title": "An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Patient is at least 18 years of age.\n* Patient is capable of understanding and complying with protocol requirements.\n* Patient has signed and dated ICF.\n* Patient has a histologically confirmed, advanced solid tumor (metastatic, recurrent, and/or unresectable) in one of the following categories: 1) anti-PD-(L)1 relapsed/refractory; 2) platinum-resistant ovarian cancer; 4) anal cancer; 5) rectal cancer; or 6) castration-resistant prostate cancer\n* Patient has failed prior standard of care therapies appropriate for their metastatic disease.\n* Patient has at least 1 measurable non-central nervous system (CNS) lesions per RECIST 1.1.\n* Patient has provided consent for pre- and on-treatment biopsies.\n* Eastern Cooperative Performance Status of 0 or 1.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patient has active autoimmune disease or other medical conditions requiring chronic systemic steroid therapy at the time of screening.\n* Patient has an unacceptable intolerance to anti-PD-(L)1 monoclonal antibody (Part B Only).\n* Patient has previously participated in a clinical study evaluating a CBL-B inhibitor.\n* Patients has untreated and/or symptomatic metastatic CNS disease.\n* Patient is currently taking any concomitant medications at Screening that have the potential to cause a clinically relevant drug-drug interaction with HST-1011.\n* Patients with a history of gastrointestinal disease that may affect absorption of the study drug, or patients who are not able to take oral medications.\n* Patient has an active infection requiring systemic therapy.\n* Patient has known or suspected infection with SARS-CoV-2 virus.",
    "miscellaneous_criteria": "Key"
}